|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...8788899091929394959697...9899» |
- Biomarker, Enrollment change: Selenium Supplementation of Patients With Cirrhosis (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=99, Terminated, Sponsor: Vanderbilt University
N=144 --> 99
- ||||| New P2 trial: Clinical Study of Lyophilized Plasma in Patients With Liver Disease (clinicaltrials.gov) - Mar 5, 2012
P2, N=100, Not yet recruiting, Sponsor: HemCon Medical Technologies, Inc
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Trial termination: Selenium Supplementation of Patients With Cirrhosis (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=99, Terminated, Sponsor: Vanderbilt University
N=144 --> 99 Recruiting --> Terminated; Insufficient funds to complete study.
- Trial initiation date: Procalcitonin in Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=42, Completed, Sponsor: Ain Shams University
Recruiting --> Terminated; Insufficient funds to complete study. Initiation date: Jan 2012 --> Apr 2012
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Enrollment change: Selenium Supplementation of Patients With Cirrhosis (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=99, Terminated, Sponsor: Vanderbilt University
Initiation date: Jan 2012 --> Apr 2012 N=144 --> 99
- | lenalidomide / Generic mfg.
New P2 trial, Metastases: Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 5, 2012
P2, N=55, Recruiting, Sponsor: National Taiwan University Hospital
- grazoprevir (MK-5172) / Merck (MSD)
New P1 trial: Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) (clinicaltrials.gov) - Mar 5, 2012
P1, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
- | Erivedge (vismodegib) / Roche
New P1 trial, Metastases: A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function (clinicaltrials.gov) - Mar 5, 2012
P1, N=31, Active, not recruiting, Sponsor: Genentech
- dusigitumab (MEDI-573) / AstraZeneca
Trial initiation date, Combination therapy, Metastases: MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (clinicaltrials.gov) - Mar 4, 2012
P1, N=6, Completed, Sponsor: MedImmune LLC
N=144 --> 99 Initiation date: Oct 2011 --> Jan 2012
- Enrollment change: Acceptability of Less Harmful Alternatives to Cigarettes (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=67, Completed, Sponsor: Roswell Park Cancer Institute
Initiation date: Oct 2011 --> Jan 2012 N=100 --> 67
- Trial completion: Acceptability of Less Harmful Alternatives to Cigarettes (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=67, Completed, Sponsor: Roswell Park Cancer Institute
N=100 --> 67 Active, not recruiting --> Completed
- Trial termination: Cytokines and the Risk of Infection in Liver Cirrhosis (clinicaltrials.gov) - Mar 1, 2012
P=N/A, N=150, Terminated, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Enrolling by invitation --> Terminated; Finding to be unable to reach the primary endpoint
- ||||||| Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Trial completion: Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine (clinicaltrials.gov) - Mar 1, 2012
P3, N=252, Completed, Sponsor: Novartis
Enrolling by invitation --> Terminated; Finding to be unable to reach the primary endpoint Active, not recruiting --> Completed
- |||||||||| ribavirin / Generic mfg.
New P3 trial: Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (clinicaltrials.gov) - Feb 29, 2012
P3, N=278, Completed, Sponsor: Gilead Sciences
- cyclosporine / Generic mfg.
Trial termination: Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation (clinicaltrials.gov) - Feb 29, 2012
P3, N=11, Terminated, Sponsor: Rennes University Hospital
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Insufficient enrollment
- anacetrapib (MK-0859) / Merck (MSD)
Enrollment change: Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039) (clinicaltrials.gov) - Feb 29, 2012
P1, N=24, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated; Insufficient enrollment N=48 --> 24
- cyclosporine / Generic mfg.
Enrollment change: Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation (clinicaltrials.gov) - Feb 29, 2012
P3, N=11, Terminated, Sponsor: Rennes University Hospital
N=48 --> 24 N=30 --> 11
- | New P2 trial: Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children (clinicaltrials.gov) - Feb 28, 2012
P2, N=76, Active, not recruiting, Sponsor: Piotr Socha
- Enrollment open: BSARTA: Behavioral Science Aspects of Rapid Test Acceptance (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=1200, Recruiting, Sponsor: California State University, Long Beach
N=30 --> 11 Not yet recruiting --> Recruiting
- Enrollment closed: The Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=26, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Metastases: Hepatic Arterial Infusion (HAI) of Abraxane (clinicaltrials.gov) - Feb 28, 2012
P1, N=56, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
New P2 trial: PERIMAX: Perioperative Treatment of Resectable Liver Metastases (clinicaltrials.gov) - Feb 26, 2012
P2, N=0, Withdrawn, Sponsor: University of Regensburg
- | brivanib alaninate (BMS-582664) / ZAI Lab
New P1 trial, Metastases: Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) (clinicaltrials.gov) - Feb 26, 2012
P1, N=12, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- Enrollment open: Identification of Hepatitis C Virus (HCV) Specific T Cells (clinicaltrials.gov) - Feb 23, 2012
P=N/A, N=40, Recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- | tegafur/uracil / Generic mfg., sorafenib / Generic mfg.
New P2 trial, Metastases: Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE (clinicaltrials.gov) - Feb 23, 2012
P2, N=143, Recruiting, Sponsor: Egyptian Society of Liver Cancer
- Trial completion: PROTOB: A Pilot Study on Whey Protein Supplementation in Non Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Feb 22, 2012
P=N/A, N=11, Completed, Sponsor: University of Lausanne
Active, not recruiting --> Recruiting Not yet recruiting --> Completed
- Trial completion: COLIBRI: Effects of Coffee on Hepatic Steatosis Induced by a High Fructose Diet (clinicaltrials.gov) - Feb 22, 2012
P=N/A, N=13, Completed, Sponsor: University of Lausanne
Not yet recruiting --> Completed Not yet recruiting --> Completed
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment open: A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon (clinicaltrials.gov) - Feb 21, 2012
P=N/A, N=500, Recruiting, Sponsor: Yonsei University
Not yet recruiting --> Completed Active, not recruiting --> Recruiting
- |||| entecavir / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Post-transplantation: Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease. (clinicaltrials.gov) - Feb 21, 2012
P2, N=112, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | methadone / Generic mfg.
Trial initiation date: Methaville: Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices (clinicaltrials.gov) - Feb 20, 2012
P3, N=197, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Initiation date: Sep 2008 --> Jan 2009
- | methadone / Generic mfg.
Enrollment change: Methaville: Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices (clinicaltrials.gov) - Feb 20, 2012
P3, N=197, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Initiation date: Sep 2008 --> Jan 2009 N=300 --> 197
- | methadone / Generic mfg.
Trial completion: Methaville: Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices (clinicaltrials.gov) - Feb 20, 2012
P3, N=197, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=300 --> 197 Not yet recruiting --> Completed
- | Pegasys (pegylated interferon ? -2a) / Roche, Roferon A (recombinant interferon alfa-2a) / Roche
Enrollment closed, IO biomarker: HB01EMVIPEG: Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients (clinicaltrials.gov) - Feb 20, 2012
P2/3, N=56, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: ANRS VITAVIC: Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders (clinicaltrials.gov) - Feb 19, 2012
P2, N=32, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting --> Active, not recruiting N=40 --> 32
- | pidilizumab (CT-011) / CureTech
Enrollment change: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection (clinicaltrials.gov) - Feb 19, 2012
P1/2, N=13, Active, not recruiting, Sponsor: CureTech Ltd
N=40 --> 32 N=20 --> 13
- pioglitazone / Generic mfg.
Enrollment change: PEGLIST C: Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance (clinicaltrials.gov) - Feb 19, 2012
P3, N=40, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=20 --> 13 N=90 --> 40
- Enrollment change, Metastases: Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer (clinicaltrials.gov) - Feb 19, 2012
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
N=90 --> 40 N=37 --> 0
- Enrollment closed: ANRS VITAVIC: Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders (clinicaltrials.gov) - Feb 19, 2012
P2, N=32, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=37 --> 0 Recruiting --> Active, not recruiting
- | pidilizumab (CT-011) / CureTech
Enrollment closed: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection (clinicaltrials.gov) - Feb 19, 2012
P1/2, N=13, Active, not recruiting, Sponsor: CureTech Ltd
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ursodeoxycholic acid / Generic mfg.
New P3 trial: Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy (clinicaltrials.gov) - Feb 17, 2012
P3, N=20, Completed, Sponsor: Turku University Hospital
- acetylcysteine solution / Generic mfg., paracetamol / Generic mfg.
Trial withdrawal, Combination therapy: Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever (clinicaltrials.gov) - Feb 16, 2012
P=N/A, N=0, Withdrawn, Sponsor: Columbia University
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- acetylcysteine solution / Generic mfg., paracetamol / Generic mfg.
Enrollment change, Combination therapy: Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever (clinicaltrials.gov) - Feb 16, 2012
P=N/A, N=0, Withdrawn, Sponsor: Columbia University
Recruiting --> Withdrawn N=200 --> 0
- grazoprevir (MK-5172) / Merck (MSD)
New P1 trial: A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) (clinicaltrials.gov) - Feb 16, 2012
P1, N=8, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Enrollment change: Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Feb 15, 2012
P3, N=0, Withdrawn, Sponsor: Accuray Incorporated
N=200 --> 0 N=160 --> 0
- |||| amphotericin b liposome / Generic mfg.
Enrollment open: AVALTRA: Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients (clinicaltrials.gov) - Feb 14, 2012
P4, N=94, Recruiting, Sponsor: Fundacion SEIMC-GESIDA
N=160 --> 0 Not yet recruiting --> Recruiting
- rifampicin / Generic mfg.
Enrollment change: Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage (clinicaltrials.gov) - Feb 13, 2012
P4, N=175, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
Not yet recruiting --> Recruiting N=60 --> 175
- | ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
New P4 trial: PEGON-study: Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB (clinicaltrials.gov) - Feb 13, 2012
P4, N=82, Active, not recruiting, Sponsor: Foundation for Liver Research
- elbasvir (MK-8742) / Merck (MSD)
New P1 trial: Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002) (clinicaltrials.gov) - Feb 13, 2012
P1, N=48, Completed, Sponsor: Merck
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen (clinicaltrials.gov) - Feb 13, 2012
P1, N=18, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
N=60 --> 175 Active, not recruiting --> Completed
- rifampicin / Generic mfg.
Trial completion: Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage (clinicaltrials.gov) - Feb 13, 2012
P4, N=175, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
Active, not recruiting --> Completed Recruiting --> Completed